OPKO Health Inc
OPK1.270USD
+0.080+6.72%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
990.32MValor de mercado
PerdaP/L TTM
Mais detalhes de OPKO Health Inc Empresa
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Informações da empresa
Código da empresaOPK
Nome da EmpresaOPKO Health Inc
Data de listagemNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Número de funcionários2997
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ Global Select Consolidated
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaOPK
Data de listagemNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
116.21M
77.50%
Chile
14.53M
9.69%
Spain
6.44M
4.29%
Mexico
6.23M
4.15%
Ireland
5.48M
3.65%
Other
1.06M
0.71%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Investidores
Investidores
Proporção
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Tipos de investidores
Investidores
Proporção
Corporation
36.58%
Hedge Fund
12.09%
Investment Advisor
10.34%
Individual Investor
10.23%
Investment Advisor/Hedge Fund
6.18%
Research Firm
1.84%
Bank and Trust
0.16%
Sovereign Wealth Fund
0.14%
Pension Fund
0.12%
Other
22.32%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
470
616.50M
77.74%
-1.20M
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
2023Q1
520
541.69M
71.63%
+67.95M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Frost Gamma Investments Trust
219.80M
27.72%
-26.90M
-10.90%
Apr 10, 2025
Rubric Capital Management LP
48.71M
6.14%
--
--
Mar 31, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.18%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Apr 02, 2025
The Vanguard Group, Inc.
29.42M
3.71%
+293.74K
+1.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
24.77M
3.12%
-514.39K
-2.03%
Mar 31, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Sculptor Capital Management, Inc
12.72M
1.6%
+12.72M
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
SPDR S&P Health Care Services ETF
0.69%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Amplify Weight Loss Drug & Treatment ETF
0.22%
VanEck Israel ETF
0.14%
iShares U.S. Healthcare Providers ETF
0.09%
Humankind US Stock ETF
0.09%
Vanguard US Momentum Factor ETF
0.08%
Invesco RAFI US 1500 Small-Mid ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
Ver Mais
SPDR S&P Health Care Services ETF
Proporção0.69%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.44%
Amplify Weight Loss Drug & Treatment ETF
Proporção0.22%
VanEck Israel ETF
Proporção0.14%
iShares U.S. Healthcare Providers ETF
Proporção0.09%
Humankind US Stock ETF
Proporção0.09%
Vanguard US Momentum Factor ETF
Proporção0.08%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.05%
iShares Biotechnology ETF
Proporção0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
